CFA Level I Exam Pass Rate Stays Above Average at 45%
In May, 45% of candidates passed the Level I test, unchanged from the percentage who were successful in February and up from 43% for those who took the exam in November, the CFA Institute said Thursday. That's also higher than the 40% average for the past decade and the lows from 2021, when exam performance was hurt by test-taking deferrals amid the Covid-19 pandemic.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
40 minutes ago
- Yahoo
Immutep Limited (IMMP) Receives Positive FDA Feedback on Future Clinical Development of Eftilagimod Alfa
Immutep Limited (NASDAQ:IMMP) is among the 12 Best Australian Stocks to Buy Right Now. On August 5, the company shared that it had received positive feedback from the U.S. FDA on the future clinical development of eftilagimod alfa (efti) for first-line treatment of head and neck squamous cell carcinoma patients with CPS <1. A line of biopharmaceutical products on a laboratory shelf waiting to be tested. The feedback stems from encouraging data from the TACTI-003 Phase 2b trial evaluating efti with MSD's anti-PD-1 KEYTRUDA (pembrolizumab). Immutep Limited (NASDAQ:IMMP) said that the FDA acknowledged the potential of the combination to address the high unmet need in patients with CPS <1 and supports its further development. Marc Voigt, CEO of Immutep Limited (NASDAQ:IMMP), shared the following remarks on the development: 'We are pleased with the FDA's feedback and guidance that underscores the high unmet need of head and neck cancer patients whose PD-L1 expression level is below one. The FDA feedback positions Immutep to evaluate options for future collaborative clinical development paths to bring a new, effective and safe treatment option to this underserved patient population.' Looking ahead, Immutep Limited (NASDAQ:IMMP) also outlined paths for future clinical development. This would include a randomised registrational trial evaluating the combination against standard-of-care therapy, or lead a smaller single-arm study on about 70-90 patients, followed by a confirmatory randomised study building on the existing findings. While we acknowledge the potential of IMMP as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 11 Best Large Cap Defense Stocks to Buy According to Analysts and 10 Best Low Priced Defense Stocks to Buy Now. Disclosure: None.
Yahoo
40 minutes ago
- Yahoo
Canaccord Genuity Initiates Coverage of Mesoblast Limited (MESO) with Buy Rating
Mesoblast Limited (NASDAQ:MESO) is among the 12 Best Australian Stocks to Buy Right Now. On August 5, Canaccord Genuity initiated coverage of the stock with a Buy rating and announced a price target of AUD 2.97 ($1.94) per share, with analyst Elyse Shapiro citing the company's promising cell therapy platform. A close up of the hand of a financial analyst, holding a copy of a report from a rating agency. The firm acknowledged Mesoblast Limited (NASDAQ:MESO)'s expertise in allogeneic therapies for severe inflammatory diseases, which use cells from a single donor, instead of requiring cells from the recipient or matched donors. Canaccord also highlighted the company's progenitor cell and mesenchymal stromal cell approach that reduces harmful inflammation by modulating the immune system. In other recent news, on July 17, Mesoblast Limited (NASDAQ:MESO) announced USD 13.2 million in gross revenue from Ryoncil sales post-launch. The drug is the first and only mesenchymal stromal cell product in the U.S. that is approved by the FDA. It became commercially available on March 28, 2025, for the treatment of steroid-refractory acute graft-versus-host disease in children. Mesoblast Limited (NASDAQ:MESO) is an Australian company focused on developing allogeneic cellular medicines to treat severe and life-threatening inflammatory conditions. While we acknowledge the potential of MESO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 11 Best Large Cap Defense Stocks to Buy According to Analysts and 10 Best Low Priced Defense Stocks to Buy Now. Disclosure: None. Sign in to access your portfolio
Yahoo
40 minutes ago
- Yahoo
Sea (SE) Is Up 20.1% After Surging Half-Year Earnings and Profitability Breakthrough – What's Changed
Sea Limited reported its half-year 2025 earnings, recording revenue of US$10.10 billion and net income of US$809.02 million, both up sharply from the previous year. This substantial increase in basic earnings per share, from US$0.10 to US$1.37, highlights a marked improvement in operating performance and profitability. Given this surge in revenue and earnings, we'll now look at how Sea's stronger profitability reshapes its longer-term investment narrative. Explore 24 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research. Sea Investment Narrative Recap To be a long-term shareholder in Sea, you need conviction in its ability to sustain strong growth across e-commerce, digital finance, and gaming in Southeast Asia and Latin America, despite rapid shifts in user preferences and rising competition. While Sea's half-year 2025 results show a surge in both revenue and net income, this positive momentum does not materially change the biggest short-term catalyst: continued profitable growth in Shopee's Brazilian and Southeast Asian markets. However, the primary risk remains aggressive competition eroding market share and threatening margins. Among the company's recent developments, the May 2025 quarterly results, where Sea also reported both higher revenues and its first consecutive periods of material net income, demonstrate an emerging trend of profitability that directly supports this earnings story. This progress bolsters investor focus on whether Sea can achieve consistent net margin expansion even as it scales in fiercely contested e-commerce and fintech arenas. Yet, contrasting recent momentum, investors should be aware that ramping up competitive spending to defend market share in Brazil or Southeast Asia could still... Read the full narrative on Sea (it's free!) Sea's outlook anticipates $33.0 billion in revenue and $4.6 billion in earnings by 2028. Achieving this would require 19.4% annual revenue growth and a $3.4 billion increase in earnings from the current $1.2 billion level. Uncover how Sea's forecasts yield a $192.84 fair value, a 9% upside to its current price. Exploring Other Perspectives Eleven Simply Wall St Community fair value estimates for Sea stock span a wide range from US$153.42 to US$252.06 per share. While optimism about future earnings growth drives many analyses, remember competition in e-commerce remains a persistent threat to sustained profitability, explore these alternative viewpoints to broaden your research. Explore 11 other fair value estimates on Sea - why the stock might be worth 13% less than the current price! Build Your Own Sea Narrative Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd. A great starting point for your Sea research is our analysis highlighting 3 key rewards that could impact your investment decision. Our free Sea research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Sea's overall financial health at a glance. Interested In Other Possibilities? The market won't wait. These fast-moving stocks are hot now. Grab the list before they run: We've found 19 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. Find companies with promising cash flow potential yet trading below their fair value. The end of cancer? These 26 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SE. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
